Stocks
Corcept Therapeutics IncorporatedCORT
NASDAQHealthcareBiotechnology$87.59
Price as of · delayed, not real-time
A commercial-stage biopharmaceutical company focused on the development and commercialization of drugs that modulate the cortisol receptor, with its lead product Korlym approved for treating Cushing's syndrome. Its pipeline includes treatments for oncology, metabolic, and psychiatric disorders, and investors track it for its revenue growth and regulatory catalysts.
52W Range: $28.66-$126.38
Congressional Interest in Corcept Therapeutics Incorporated (CORT)
1 member of Congress has disclosed 3 trades in Corcept Therapeutics Incorporated (CORT), a Healthcare company. The buy/sell breakdown shows 3 purchases versus 0 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
3
Unique Politicians
1
Buys
3
Sells
0
Who in Congress Is Trading CORT?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2017-12-15 | JAMES B. RENACCI | buy | $15K-$50K |
| 2017-11-20 | JAMES B. RENACCI | buy | $1K-$15K |
| 2017-10-11 | JAMES B. RENACCI | buy | $1K-$15K |